| The Company’s concerted focus on the semi-acute therapy is the crux of the Lupin division, which has enabled the Company to attain market leadership in the Anti-TB segment of IPM. It continues to lead the pack in the anti-TB segment, as well as maintain its presence in the cardiovascular, diabetic, asthma and CNS space. The Lupin division now commands 46% market share in a INR 2,920 million anti-TB market and grew by 7% during the year.
Key Products : Lupin Pharma
|
Product |
Therapeutic segment
|
Product Rank in the relevant segment |
|
R-Cinex |
Anti-TB |
1 |
|
AKT |
Anti-TB |
1 |
|
Akurit |
Anti-TB |
1 |
|
R-CIN |
Anti-TB |
1 |
|
G-CIN |
Gemifloxacin |
1 |
|
Combutol |
Ethambutol & Comb. |
1 |
|
Pyzina |
Pyrazinamide Plain |
2 |
| 
